141 related articles for article (PubMed ID: 38224566)
1. Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts.
Ji J; Dragojevic S; Callaghan CM; Smith EJ; Talele S; Zhang W; Connors MA; Mladek AC; Hu Z; Bakken KK; Sarkaria PP; Carlson BL; Burgenske DM; Decker PA; Rashid MA; Jang MH; Gupta SK; Eckel-Passow JE; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2024 May; 23(5):662-671. PubMed ID: 38224566
[TBL] [Abstract][Full Text] [Related]
2. Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases.
Talele S; Zhang W; Oh JH; Burgenske DM; Mladek AC; Dragojevic S; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2022 Jun; 381(3):217-228. PubMed ID: 35370138
[TBL] [Abstract][Full Text] [Related]
3. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown
Timme CR; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Jun; 17(6):1207-1216. PubMed ID: 29549168
[TBL] [Abstract][Full Text] [Related]
4. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.
Khan AJ; Wall B; Ahlawat S; Green C; Schiff D; Mehnert JM; Goydos JS; Chen S; Haffty BG
Clin Cancer Res; 2011 Apr; 17(7):1807-14. PubMed ID: 21325066
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
6. Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.
Wall BA; Yu LJ; Khan A; Haffty B; Goydos JS; Chen S
Pigment Cell Melanoma Res; 2015 Jan; 28(1):105-9. PubMed ID: 25363352
[TBL] [Abstract][Full Text] [Related]
7. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models.
Durant ST; Zheng L; Wang Y; Chen K; Zhang L; Zhang T; Yang Z; Riches L; Trinidad AG; Fok JHL; Hunt T; Pike KG; Wilson J; Smith A; Colclough N; Reddy VP; Sykes A; Janefeldt A; Johnström P; Varnäs K; Takano A; Ling S; Orme J; Stott J; Roberts C; Barrett I; Jones G; Roudier M; Pierce A; Allen J; Kahn J; Sule A; Karlin J; Cronin A; Chapman M; Valerie K; Illingworth R; Pass M
Sci Adv; 2018 Jun; 4(6):eaat1719. PubMed ID: 29938225
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting DNA-PK
Mamo T; Mladek AC; Shogren KL; Gustafson C; Gupta SK; Riester SM; Maran A; Galindo M; van Wijnen AJ; Sarkaria JN; Yaszemski MJ
Biochem Biophys Res Commun; 2017 Apr; 486(2):307-313. PubMed ID: 28300555
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells.
Munshi A; Kurland JF; Nishikawa T; Chiao PJ; Andreeff M; Meyn RE
Mol Cancer Ther; 2004 Aug; 3(8):985-92. PubMed ID: 15299081
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer.
Gordhandas SB; Manning-Geist B; Henson C; Iyer G; Gardner GJ; Sonoda Y; Moore KN; Aghajanian C; Chui MH; Grisham RN
Sci Rep; 2022 Jan; 12(1):974. PubMed ID: 35046420
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of DNA-PKcs activity re-sensitizes uveal melanoma cells to radio- and chemotherapy.
Zhang B; Wu H; Hao J; Wu Y; Yang B
Biochem Biophys Res Commun; 2020 Feb; 522(3):639-646. PubMed ID: 31785810
[TBL] [Abstract][Full Text] [Related]
12. A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.
van Bussel MTJ; Awada A; de Jonge MJA; Mau-Sørensen M; Nielsen D; Schöffski P; Verheul HMW; Sarholz B; Berghoff K; El Bawab S; Kuipers M; Damstrup L; Diaz-Padilla I; Schellens JHM
Br J Cancer; 2021 Feb; 124(4):728-735. PubMed ID: 33230210
[TBL] [Abstract][Full Text] [Related]
13. NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor.
Yu L; Shang ZF; Hsu FM; Zhang Z; Tumati V; Lin YF; Chen BP; Saha D
Oncotarget; 2015 Feb; 6(6):3848-60. PubMed ID: 25714019
[TBL] [Abstract][Full Text] [Related]
14. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
[TBL] [Abstract][Full Text] [Related]
15. TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.
Lee Y; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Mol Cancer Ther; 2017 Jan; 16(1):16-24. PubMed ID: 28062703
[TBL] [Abstract][Full Text] [Related]
16. A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.
Samuels M; Falkenius J; Bar-Ad V; Dunst J; van Triest B; Yachnin J; Rodriguez-Gutierrez A; Kuipers M; You X; Sarholz B; Locatelli G; Becker A; Troost EGC
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):743-756. PubMed ID: 37751793
[TBL] [Abstract][Full Text] [Related]
17. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.
Kahn J; Hayman TJ; Jamal M; Rath BH; Kramp T; Camphausen K; Tofilon PJ
Neuro Oncol; 2014 Jan; 16(1):29-37. PubMed ID: 24311635
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.
Brooks C; Sheu T; Bridges K; Mason K; Kuban D; Mathew P; Meyn R
Radiat Oncol; 2012 Sep; 7():154. PubMed ID: 22967802
[TBL] [Abstract][Full Text] [Related]
20. DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
Haines E; Nishida Y; Carr MI; Montoya RH; Ostermann LB; Zhang W; Zenke FT; Blaukat A; Andreeff M; Vassilev LT
Sci Rep; 2021 Jun; 11(1):12148. PubMed ID: 34108527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
